The routine, twice-weekly asymptomatic Covid-19 testing by pharmacy staff can be paused from the end of August.
The health regulator announced that regular asymptomatic testing for Covid-19 will be paused in all remaining health and care settings from 31 August 2022.
Currently all pharmacy staff test twice-weekly for Covid-19, using a self-administered Lateral Flow Device (LFD) test at home.
"Prevalence of Covid-19 in the community has fallen and remains at a comparatively low level as we emerge from the current Omicron wave. This means that the
likelihood that individuals entering healthcare settings are infectious has also reduced and the relative risk of onward transmission into these settings is lower."
The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups.
The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms.
Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided.
Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams
are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.
The community pharmacy staff in Scotland will not be required to work for a minimum of five full days if they test positive for Covid-19.
The Scottish health secretary Humza Yousaf has clarified that health and social care employees, including community pharmacists, will have to follow the guidance
on managing staff with symptoms of a respiratory infection, or a positive Covid-19 test.
While responding to Jackie Baillie (Dumbarton) (Scottish Labour Party) written parliamentary question, Humza said, "If they work with patients or service users in
face-to-face settings, they can return to work if they have had two consecutive negative LFD test results (taken at least 24 hours apart)."
Jackie asked the Scottish government, "what its position is on the actions of Well Pharmacy, in light of reports that the company is insisting that staff who test
positive for COVID-19 continue to work when they are in patient-facing roles and dealing with clinically vulnerable people?"
The Pharmacists' Defence Association said: "This means that Well pharmacy will have to change their policy in Scotland and no longer allow Covid positive staff to
work in their pharmacies."
Community pharmacies must be involved in future planning for public health emergencies, especially in cases where a quick response is needed such as the Covid-19 pandemic, a European-wide research has recommended.
The project, co-led by the University of Huddersfield professor Zaheer-Ud-Din Babar in medicines and healthcare, focuses on how community pharmacies dealt with the pandemic, covering 31 pharmacy interventions on Covid-19 in 32 countries in Europe.
The interventions include prevention, response, and recovery measures. It also covers improved access to medicines, expanded powers granted to pharmacies, rapid antigen testing, along with Covid-19 vaccination.
Community pharmacists in the US, Canada, and Australia have been engaged in pandemic prevention, preparedness, and response strategic guidance after the 2009 flu pandemic.
The aim of the research is to map the current reported practice and trends and review the pharmacies' intervention in Europe.
Well Pharmacy is urging those eligible to take up the offer of a further Covid booster jab this spring.
Adults aged 75 years and over and anyone over 5 years old and are immunosuppressed - such as those who are undergoing chemotherapy or have had an organ
transplant - are entitled to have a further Covid booster jab from mid-April, said one of the UK's largest community pharmacy chains.
Taking part in the vaccination programme again, Well Pharmacy is encouraging people to book another booster as soon as they are contacted by the NHS - which
should be at least six months after their previous booster.
The national booking site for those eligible opens this week.
The jabs have been updated since the vaccines were introduced to now target newer strains of Covid-19, Well said in a press release issued on Wednesday, 5 April.
Thousands of people are still testing positive for Covid each week according to Government data, and - while hospitalisations are down - a large number of people
are still being hospitalised with Covid, so getting jabbed is as important as ever.
And the Joint Committee on Vaccination and Immunisation (JCVI) recently confirmed that hospital admissions last autumn highlighted that the risk of becoming
seriously ill from coronavirus was noticeably higher in people over 75.
American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations.
The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of
neutralising antibodies after vaccination.
The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20.
After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine.
It recommended that the test be performed at least 14 days after completing the vaccination cycle.
In his maiden speech delivered to community pharmacy since becoming new minister with responsibility for the sector, Will Quince MP said he's determined to be
"your champion" and "voice in government".
Addressing delegates on Wednesday (Oct 12) as chief guest at the 22nd Pharmacy Business Awards in central London, he praised community pharmacy for delivering 25
million Covid-19 vaccines, five million flu jabs, 200 million lateral flow testing kits and millions of medicines throughout the pandemic.
"These local efforts became the national success story," he told over 600 attendees at a gala dinner held at the iconic Park Plaza Westminster Bridge hotel
overlooking the Houses of Parliament.
'We need you now'
Quince, who was appointed minister of state at the Department of Health and Social Care on 7 September 2022, added: "Just as we needed you in the pandemic, we
need you now," highlighting the vital role of community pharmacy in realising the secretary of state (Thérèse Coffey)'s vision, particularly in regard to her
much talked about 'Plan for Patients'.
Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June.
Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe.
The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost.
The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven.
Free pick up from pharmacies
The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.
Britain has started counting possible Covid-19 reinfections in its daily coronavirus data, changing its approach to reflect the increased number of people
catching the disease for a second time as the Omicron variant predominates.
The UK Health Security Agency (UKHSA) added around 840,000 cases to the cumulative total, taking it to 17.3 million coronavirus infections reported.
Britain's daily Covid statistics previously would only count people who had tested positive for the first time to avoid double-counting people who had received multiple positive test results for the same infection.
However, with variants such as Omicron leading to an increase in reinfections, the UKHSA said it would change its method to treat positive tests as separate infections if there was at least 90 days between test results. The change took effect on Monday (January 31).
"Reinfection remained at very low levels until the start of the Omicron wave. It is right that our daily reporting processes reflect how the virus has changed," said Steven Riley, UKHSA's Director General of Data and Analytics.
Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients.
The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery.
The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022.
Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19.
People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.
Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.
A second Global Covid-19 Summit will be held virtually next month for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on Monday (April18).
"The emergence and spread of new variants, like Omicron, have reinforced the need for a strategy aimed at controlling Covid-19 worldwide," the White House said in a news release with the Group of Seven and Group of 20 nations.
The announcement comes amid a surge of Covid-19 cases around the world prompted by easily transmissible variants of the virus.
China's most populous city, Shanghai, is trying to return to normal after a nearly three-week shutdown, which, along with wider China curbs, are taking a toll on the world's No. 2 economy.
The summit will build on efforts and commitments made at the first global summit in September, including getting more people vaccinated, sending tests and treatments to highest-risk populations, expanding protections to health care workers and generating financing for pandemic preparedness, the statement said.
The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative
and may have resulted in the deaths of about 20 people.
Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020.
Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised.
An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have
misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.
The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
Labour Party leader Keir Starmer leader has tested positive for Covid-19 for a second time, a spokesperson confirmed on Wednesday (January 5).
Starmer had been due to face prime minister Boris Johnson at a question and answer session in parliament later today. His deputy, Angela Rayner, will take his place, the spokesperson added.
Starmer had tested positive for Covid-19 last October and self-isolated four times after coming into contact with other positive cases on several occasions.
Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report.
Demand also has been hampered by the perception that Omicron infections are not that severe.
Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial.
Thousands of people still die from Covid-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.
Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a
rise in infections, the head of the World Health Organization said on Friday (December 2).
The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position
to end the pandemic.
"We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday.
The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination.
"Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality,"
Tedros said.
COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.
The world's first human challenge trial in which volunteers were deliberately exposed to Covid-19 to advance research into the disease was found to be safe in
healthy young adults, one of the companies running the study said on Wednesday.
The data supports the safety of this model which could theoretically provide a "plug and play" platform for testing therapies and vaccines using the original
Covid-19 strain as well as variants of the virus, Open Orphan, which carried out the study, said in a statement.
Open Orphan is running the project, launched a year ago, with Imperial College London, the UK government's vaccines task force and the clinical company hVIVO.
The trial infected 36 healthy male and female volunteers aged 18-29 years with the original SARS-CoV-2 strain of the virus and closely monitored them in a controlled
quarantined setting. They will be followed up for 12 months after discharge from the quarantine facility.
The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been
labelled a global health emergency by the World Health Organization.
The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed
PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox.
Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have
been proven to help hasten recovery in those who develop the disease.
The UK has over 3,000 confirmed cases of monkeypox.
The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and
pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks.
Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European
Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.